Dhunseri Ventures Q1 results: Revenue up 7.56% YoY to Rs 173.48 crore, Net Profit down 1.28% YoY
Revenue from operations stood at Rs 173.48 crore in Q1 FY26, marking a 7.56% year-on-year growth from Rs 161.27 crore in Q1 FY25, and a 17.80% increase from Rs 1,472.27 crore in Q4 FY25. Total income came in at Rs 1,932.50 crore, compared to Rs 1,831.07 crore a year ago.
On the expense side, total costs were Rs 1,273.12 crore in Q1 FY26 versus Rs 1,334.68 crore last year, with lower material costs offset by a rise in finance costs to Rs 269.05 crore from Rs 23.33 crore in the year-ago quarter.
Profit before tax stood at Rs 92.74 crore against Rs 85.86 crore in Q1 FY25. The company's share of profit from equity accounted investees was Rs 26.81 crore this quarter, compared to Rs 36.22 crore last year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
36 minutes ago
- Business Upturn
Alembic Pharma gains as USFDA approves Macitentan tablets for pulmonary arterial hypertension
By Aditya Bhagchandani Published on August 19, 2025, 11:18 IST Shares of Alembic Pharmaceuticals Ltd were in focus on Tuesday, August 19, after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Macitentan Tablets, 10 mg. The product is a generic version of Actelion Pharmaceuticals' Opsumit tablets and is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults to reduce the risk of disease progression and hospitalization. According to IQVIA data, the drug has an estimated market size of $1.18 billion for the 12 months ending June 2025. With this nod, Alembic's cumulative USFDA approvals now stand at 224 Abbreviated New Drug Applications (ANDAs), including 203 final approvals and 21 tentative approvals. The approval adds to the company's growing US generics portfolio, which has been a key driver of international business. Founded in 1907, Alembic is a vertically integrated pharmaceutical company with a strong presence in branded generics in India and a well-established footprint in the global generics market. The company manufactures and markets products across multiple therapeutic segments through its R&D-driven operations. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
39 minutes ago
- Business Upturn
Kernex Microsystems shares rise over 2% after bagging Rs 151 crore KAVACH order from West Central Railway
By Aditya Bhagchandani Published on August 19, 2025, 10:44 IST Shares of Kernex Microsystems (India) Ltd gained over 2% in Monday's trade after the company announced a fresh order win for the Indian Railways' indigenous KAVACH Automatic Train Protection (ATP) system. At 10:43 am, the stock was trading at ₹1,076 apiece on the NSE, up 2.31% (₹24.30) from the previous close of ₹1,051.70. During the session, the stock touched a high of ₹1,079.70 and a low of ₹999.20. Kernex currently commands a market capitalisation of ₹18.10 billion and has delivered sharp gains from its 52-week low of ₹621.55, though still off its high of ₹1,580. The company, through its Kernex–KEC Consortium, secured an order worth ₹151.41 crore (including GST) from West Central Railway, Bhopal Division. The scope of work involves deployment of the KAVACH ATP system on the UHF backbone along with optical fibre cable (OFC) and route diversity. The project will be completed in 600 days across sections including Itarsi–Khandwa and Bina–Ruthiyai . With this contract, Kernex's cumulative KAVACH order book since April 2024 has risen to ₹3,136.53 crore, underscoring strong momentum in the rail safety modernisation drive. Kernex, a niche player in railway safety and signalling solutions, continues to benefit from the government's aggressive push towards rail safety. Analysts say the company's expanding execution pipeline could further support stock performance, though valuations remain on the higher side with a P/E ratio of 36.03. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
39 minutes ago
- Business Upturn
Kernex Microsystems gains order worth Rs 151 crore from West Central Railways
Shares of Kernex Microsystems (India) Ltd are likely to be in focus after the company announced that it has secured a new order worth ₹151.41 crore (including GST) from West Central Railway, Bhopal Division. The contract has been awarded to the Kernex–KEC Consortium and will involve the provision of the KAVACH indigenous Automatic Train Protection (ATP) system on the UHF backbone along with optical fibre cable (OFC) and route diversity across key railway sections. According to the company's exchange filing, the project has a completion timeline of 600 days and will cover sections including Itarsi (Excl.)–Khandwa (Excl.) and Bina (Excl.)–Ruthiyai , among others in the Bhopal Division. This latest win takes Kernex's cumulative KAVACH order book—including consortium and joint venture partners—since April 1, 2024, to ₹3,136.53 crore. The order underscores the growing adoption of KAVACH, the Indian Railways' indigenous train collision avoidance system, across the network as part of its safety and modernisation drive. Kernex, which specialises in railway signalling and safety solutions, has been a key beneficiary of the government's focus on deploying KAVACH across high-density routes. With this contract, the company has further strengthened its execution pipeline, which now spans several zones of Indian Railways. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
